CA3069526A1 - Compounds for the reducing lipotoxic damage - Google Patents
Compounds for the reducing lipotoxic damage Download PDFInfo
- Publication number
- CA3069526A1 CA3069526A1 CA3069526A CA3069526A CA3069526A1 CA 3069526 A1 CA3069526 A1 CA 3069526A1 CA 3069526 A CA3069526 A CA 3069526A CA 3069526 A CA3069526 A CA 3069526A CA 3069526 A1 CA3069526 A1 CA 3069526A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- compound
- subject
- acceptable salt
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
- C07D305/12—Beta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531454P | 2017-07-12 | 2017-07-12 | |
| US62/531,454 | 2017-07-12 | ||
| PCT/US2018/041796 WO2019014434A1 (en) | 2017-07-12 | 2018-07-12 | COMPOUNDS FOR REDUCING LIPOTOXIC LESIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3069526A1 true CA3069526A1 (en) | 2019-01-17 |
Family
ID=65002124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3069526A Pending CA3069526A1 (en) | 2017-07-12 | 2018-07-12 | Compounds for the reducing lipotoxic damage |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US11339126B2 (enExample) |
| EP (2) | EP4218753B1 (enExample) |
| JP (1) | JP7224331B2 (enExample) |
| KR (1) | KR102679975B1 (enExample) |
| CN (1) | CN111343999B (enExample) |
| AU (2) | AU2018300985B2 (enExample) |
| BR (1) | BR112020000635B1 (enExample) |
| CA (1) | CA3069526A1 (enExample) |
| ES (1) | ES2934883T3 (enExample) |
| IL (1) | IL271884B2 (enExample) |
| PL (1) | PL3651784T3 (enExample) |
| SG (1) | SG11202000239XA (enExample) |
| WO (1) | WO2019014434A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4218753B1 (en) | 2017-07-12 | 2025-12-03 | Mayo Foundation for Medical Education and Research | Novel lipase inhibitor and uses thereof |
| JP2024517699A (ja) * | 2021-04-23 | 2024-04-23 | パナフィナ，インコーポレイテッド | リプスタチン誘導体を合成する方法 |
| CN114560887B (zh) * | 2022-02-15 | 2024-01-26 | 安徽美致诚药业有限公司 | 一种制备奥利司他的中间体的制备方法 |
| CN119031909A (zh) * | 2022-03-31 | 2024-11-26 | 梅约医学教育与研究基金会 | 用于治疗胰腺疾病和病症的方法和材料 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA859575B (en) * | 1984-12-21 | 1986-08-27 | Hoffmann La Roche | Oxetanones |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| IL97148A (en) * | 1990-02-26 | 1996-11-14 | Hoffmann La Roche | Oxetanones a process for their manufacture and pharmaceutical compositions containing them |
| FR2754827B1 (fr) | 1996-10-17 | 1998-12-24 | Biocem | Lipases pancreatiques et/ou colipases recombinantes et polypeptides dervies produits par les plantes, leurs procedes d'obtention et leurs utilisations |
| FR2758143B1 (fr) | 1997-01-07 | 1999-02-19 | Laphal Laboratoire De Pharmaco | Inhibiteurs specifiques de la lipase pancreatique et leurs applications |
| US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US20040018197A1 (en) | 2002-04-26 | 2004-01-29 | Promega Corporation | Treatment for weight loss |
| DE102004009076A1 (de) | 2004-02-23 | 2005-10-27 | Solvay Pharmaceuticals Gmbh | Alkylcarbamat-substituierte β-Lactone, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| EP1803714A1 (en) | 2005-12-27 | 2007-07-04 | KRKA, tovarna zdravil, d.d., Novo mesto | Process for preparing crystalline forms of orlistat |
| EP2212305A4 (en) | 2007-10-31 | 2011-10-26 | Burnham Inst Medical Research | BETA-lactone |
| US9023887B2 (en) | 2011-04-15 | 2015-05-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Lipase inhibitors for the treatment of pancreatitis and organ failure |
| US20150099800A1 (en) | 2012-05-24 | 2015-04-09 | Northeastern University | Novel lipase inhibitors, reporter substrates and uses thereof |
| WO2016002541A1 (ja) | 2014-06-30 | 2016-01-07 | 日立工機株式会社 | 電動工具 |
| EP3237011B1 (en) | 2014-12-22 | 2021-11-10 | Université Libre de Bruxelles | Composition comprising vancomycin and orlistat |
| US20180319894A1 (en) | 2015-11-03 | 2018-11-08 | Mayo Foundation For Medical Education And Research | Using colipase inhibitors to treat pancreatitis |
| EP4218753B1 (en) | 2017-07-12 | 2025-12-03 | Mayo Foundation for Medical Education and Research | Novel lipase inhibitor and uses thereof |
-
2018
- 2018-07-12 EP EP22197886.9A patent/EP4218753B1/en active Active
- 2018-07-12 EP EP18831486.8A patent/EP3651784B1/en active Active
- 2018-07-12 CA CA3069526A patent/CA3069526A1/en active Pending
- 2018-07-12 BR BR112020000635-1A patent/BR112020000635B1/pt active IP Right Grant
- 2018-07-12 WO PCT/US2018/041796 patent/WO2019014434A1/en not_active Ceased
- 2018-07-12 KR KR1020207003413A patent/KR102679975B1/ko active Active
- 2018-07-12 AU AU2018300985A patent/AU2018300985B2/en active Active
- 2018-07-12 PL PL18831486.8T patent/PL3651784T3/pl unknown
- 2018-07-12 ES ES18831486T patent/ES2934883T3/es active Active
- 2018-07-12 SG SG11202000239XA patent/SG11202000239XA/en unknown
- 2018-07-12 CN CN201880057761.7A patent/CN111343999B/zh active Active
- 2018-07-12 JP JP2020501125A patent/JP7224331B2/ja active Active
- 2018-07-12 US US16/629,842 patent/US11339126B2/en active Active
-
2020
- 2020-01-07 IL IL271884A patent/IL271884B2/en unknown
-
2022
- 2022-04-20 US US17/725,281 patent/US11623915B2/en active Active
-
2023
- 2023-03-03 US US18/178,062 patent/US11976040B2/en active Active
-
2024
- 2024-04-17 US US18/637,793 patent/US12325690B2/en active Active
- 2024-12-11 AU AU2024278291A patent/AU2024278291A1/en active Pending
-
2025
- 2025-05-14 US US19/207,836 patent/US20250340512A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11623915B2 (en) | Compounds for the reducing lipotoxic damage | |
| US11339136B2 (en) | Compounds and compositions for treating conditions associated with NLRP activity | |
| JP6989505B2 (ja) | Ｍａｌｔ１阻害剤およびその使用 | |
| JP2021073314A (ja) | ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ | |
| BR112018004863B1 (pt) | Compostos usados para a prevenção ou aplicação terapêutica de hiperuricemia ou gota | |
| KR20170113546A (ko) | 옥사티아진-유사 화합물의 제조방법 | |
| JP6563998B2 (ja) | 治療計画 | |
| US20220184032A1 (en) | Indoline derivatives for treatment and/or prevention of fibrosis diseases | |
| JPWO2003031414A1 (ja) | 新規なヘテロ環化合物および抗炎症薬 | |
| RU2776343C2 (ru) | Соединения для снижения липотоксического повреждения | |
| WO2023272571A1 (zh) | 2,3-环氧丁二酰衍生物的医药用途 | |
| HK40029799B (en) | Compounds for the reducing lipotoxic damage | |
| HK40029799A (en) | Compounds for the reducing lipotoxic damage | |
| CA2717495C (en) | Fullerene therapies for inflammation | |
| JPWO1996006825A1 (ja) | グアニジノメチルシクロヘキサンカルボン酸エステル誘導体 | |
| EP3868376A1 (en) | Method of treating bacterial infections and pharmaceutical composition for treating bacterial infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230615 |
|
| EEER | Examination request |
Effective date: 20230615 |
|
| EEER | Examination request |
Effective date: 20230615 |